Humoral in Medical Technology

ImmunoVaccine Technologies' DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases

... depot effect that significantly enhances vaccine induced cell-mediated and humoral immunity. The efficacy of a single dose of a DepoVax(TM) formulation was ... therapeutic cancer formulations in the clinic this coming year." For the humoral response, a recombinant H5 antigen was used. IVT immunized models once ...

VIRxSYS to Host a Web Conference to Announce Clinical Trial Update

... study, VRX1023 delivered antigens that induced long-lasting cellular and humoral immune responses, better than those seen with other viral vectors, a ... destruction of CD4 T cells that ensues. Activation of both cellular and humoral immunity can also halt the slow destruction of the immune system by the ...

University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients

... organ rejection. Several patients showed evidence of cellular (n = 8) or humoral (n = 2) rejection while under monitoring. The patients demonstrating ... after good immune function was restored. The two patients demonstrating humoral rejections showed no changes in CMI. Finally, of the 23 patients who ...

Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced

... treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital ... treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital ...

Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease

... treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital ... treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital ...

Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer

... of the resected tumour. Secondary objectives include assessing the anti-tumour activity and safety profile of REOLYSIN(R), and monitoring the humoral and cellular immune response to REOLYSIN(R). Eligible patients include those with histologically proven colorectal cancer, planned for potentially ...

GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009.

... by stimulated T lymphocytes. As the disease progresses from sub clinical to clinical stages, the cell-mediated immune response wanes, and a strong humoral response predominates. About Real Time PCR Traditionally, PCR is performed in a tube and when the reaction is complete the products ...

Baxter Initiates Phase III Trial for the Treatment of Alzheimer's Disease

... posted. About GAMMAGARD LIQUID GAMMAGARD LIQUID is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include, but are not limited to, congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, ...

AlphaVax Continues to Expand the Use of Its Vaccine Platform

... during the first grant period demonstrated that AlphaVax's smallpox vaccine, which expresses four, highly conserved poxvirus proteins, could provide humoral responses comparable to those obtained with a licensed vaccine. Furthermore, the AlphaVax vaccine protected mice against vaccinia virus challenge and ...

BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine

... during second half year 2009. The therapeutic vaccine, based on the company's MVA-BN(R) technology, is designed to generate cellular and humoral immune responses to PSA and PAP (prostate specific antigen and prostatic acid phosphatase), which are both well-known prostate cancer tumor targets. ...

New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma

... resultant data suggest a positive trend for clinical response. These data also demonstrate the induction of a desirable immune response, including humoral and cellular responses. These study results represent a second positive trend for clinical activity for the novel MAGE-A3 cancer immunotherapeutic, ...

VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia

... We have seen significant long term response against HIV proteins both in terms of cellular immunity, which is mediated by T Lymphocytes, and humoral immunity, which is mediated by antibodies." VIRxSYS takes a different approach as anti-HIV vaccine than recently publicized failed vaccines. The ...

Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously

... GAMMAGARD LIQUID 10% (known as KIOVIG(TM) in Europe) is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, ...

AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial

... vaccines. The study was a placebo-controlled, randomized, double-blind trial in healthy adults, 18-40 years old, which evaluated the safety and humoral and cellular immune responses after one or two inoculations. The replicon vector expressed the hemagglutinin (HA) gene derived from the ...

VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)

... to reaching the maximum tolerated dose (MTD), dose dependent activities were observed in protocol-specified surrogate biomarkers in both cellular and humoral immunologic functions. VioQuest intends to begin enrolling patients in a follow-on Phase IIa. (Logo: ...

Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting

... technology was well tolerated and significantly enhanced both humoral (antibody) and cellular (T-cell) immune responses when compared with ... DNA vaccine against a malaria parasite-specific antigen not only enhanced humoral and cellular immune responses, but more importantly caused a significant ...

New England Journal of Medicine Publishes New Data on Gardasil, Merck's Cervical Cancer Vaccine

... animal studies with analogous (animal, not human) papillomaviruses suggest that the efficacy of L1 VLP vaccines is mediated by the development of humoral immune responses. CLINICAL STUDIES CIN 2/3 and AIS are the immediate and necessary precursors of squamous cell carcinoma and adenocarcinoma ...

Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18

... animal studies with analogous (animal, not human) papillomaviruses suggest that the efficacy of L1 VLP vaccines is mediated by the development of humoral immune responses. CLINICAL STUDIES CIN 2/3 and AIS are the immediate and necessary precursors of squamous cell carcinoma and adenocarcinoma ...

News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics

... a granulocyte macrophage colony stimulating factor (GM-CSF) gene. The intent of this two-step approach is to bring a complement of cells involved in humoral and cell-mediated immunity in close proximity to the immunizing tumor antigens in a concerted effort to assist in tumor eradication and to promote a ...

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types

... AS04 Adjuvanted HPV 16/18 L1 VLP Vaccine. Presented at AACR Medical Meeting. April 17, 2007. 5. Giannini SL, Hanon E, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04)compared to ...